These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

569 related articles for article (PubMed ID: 17721278)

  • 1. PGDS, a novel technique combining chromogenic in situ hybridization and immunohistochemistry for the assessment of ErbB2 (HER2/neu) status in breast cancer.
    Ni R; Mulligan AM; Have C; O'Malley FP
    Appl Immunohistochem Mol Morphol; 2007 Sep; 15(3):316-24. PubMed ID: 17721278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [HER-2 oncogene amplification assessment in invasive breast cancer by dual-color in situ hybridization (dc-CISH): a comparative study with fluorescent in situ hybridization (FISH)].
    Akhdar A; Bronsard M; Lemieux R; Geha S
    Ann Pathol; 2011 Dec; 31(6):472-9. PubMed ID: 22172120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization.
    Jimenez RE; Wallis T; Tabasczka P; Visscher DW
    Mod Pathol; 2000 Jan; 13(1):37-45. PubMed ID: 10658908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene protein detection platform--a comparison of a new human epidermal growth factor receptor 2 assay with conventional immunohistochemistry and fluorescence in situ hybridization platforms.
    Stålhammar G; Farrajota P; Olsson A; Silva C; Hartman J; Elmberger G
    Ann Diagn Pathol; 2015 Aug; 19(4):203-10. PubMed ID: 25921313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma.
    Couturier J; Vincent-Salomon A; Nicolas A; Beuzeboc P; Mouret E; Zafrani B; Sastre-Garau X
    Mod Pathol; 2000 Nov; 13(11):1238-43. PubMed ID: 11106082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of chromogenic in situ hybridization (CISH) in the evaluation of HER2 status in breast carcinoma: comparison with immunohistochemistry and FISH.
    Li-Ning-T E; Ronchetti R; Torres-Cabala C; Merino MJ
    Int J Surg Pathol; 2005 Oct; 13(4):343-51. PubMed ID: 16273190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of HER2/neu status: a pilot study comparing HER2/neu dual in situ hybridization DNA probe cocktail assay performed on cell blocks to immunohistochemisty and fluorescence in situ hybridization performed on histologic specimens.
    Hartman AK; Gorman BK; Chakraborty S; Mody DR; Schwartz MR
    Arch Pathol Lab Med; 2014 Apr; 138(4):553-8. PubMed ID: 24678687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chromogenic in situ hybridization (CISH) to detect HER2 gene amplification in breast and gastric cancer: comparison with immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH).
    Kiyose S; Igarashi H; Nagura K; Kamo T; Kawane K; Mori H; Ozawa T; Maeda M; Konno K; Hoshino H; Konno H; Ogura H; Shinmura K; Hattori N; Sugimura H
    Pathol Int; 2012 Nov; 62(11):728-34. PubMed ID: 23121603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HER-2/neu in breast cancer: a comparative study between histology, immunohistochemistry, and molecular technique (FISH).
    Rossi E; Ubiali A; Cadei M; Balzarini P; Valagussa E; Lucini L; Alpi F; Galletti A; Fontana L; Tedoldi C; Grigolato P
    Appl Immunohistochem Mol Morphol; 2006 Jun; 14(2):127-31. PubMed ID: 16785778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of Her-2/neu oncogene in breast carcinoma by chromogenic in situ hybridization in cytologic specimens.
    Lin F; Shen T; Prichard JW
    Diagn Cytopathol; 2005 Dec; 33(6):376-80. PubMed ID: 16299744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma.
    Zhao J; Wu R; Au A; Marquez A; Yu Y; Shi Z
    Mod Pathol; 2002 Jun; 15(6):657-65. PubMed ID: 12065780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Analysis of HER2 gene amplification and its protein expression in 165 cases of breast carcinoma: comparison of chromogenic in-situ hybridization and immunohistochemistry].
    Shen DH; Wang FH; Yu YZ
    Zhonghua Bing Li Xue Za Zhi; 2007 Jul; 36(7):457-60. PubMed ID: 17845758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Analysis of HER2 gene status in breast cancer with HER2 protein overexpression].
    Zeng X; Liang ZY; Wu SF; Zhou WX; Gao J; Liu TH
    Zhonghua Bing Li Xue Za Zhi; 2006 Oct; 35(10):584-8. PubMed ID: 17134563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation assay enables accurate assessment of HER2 genomic status in gastric cancer and has potential utility in HER2 testing of biopsy samples.
    Yan B; Yau EX; Choo SN; Ong CW; Yong KJ; Pang B; Salto-Tellez M
    J Clin Pathol; 2011 Oct; 64(10):880-3. PubMed ID: 21757431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual-colour CISH is a reliable alternative to FISH for assessment of topoisomerase 2-alpha amplification in breast carcinomas.
    García-Caballero T; Prieto O; Vázquez-Boquete A; Gude F; Viaño P; Otero M; Curiel T; Fernández-Rodríguez B; Parrado C; Fraga M; Antúnez JR
    Breast Cancer Res Treat; 2014 Jan; 143(1):81-9. PubMed ID: 24292870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoplex LightCycler polymerase chain reaction quantitation of the HER2 gene for quality assurance of HER2/neu testing by immunohistochemistry and fluorescence in situ hybridization.
    Layfield LJ; Willmore-Payne C; Isom G; Holden JA
    Appl Immunohistochem Mol Morphol; 2008 Dec; 16(6):562-7. PubMed ID: 18948825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry.
    Salido M; Tusquets I; Corominas JM; Suarez M; Espinet B; Corzo C; Bellet M; Fabregat X; Serrano S; Solé F
    Breast Cancer Res; 2005; 7(2):R267-73. PubMed ID: 15743507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization.
    Isola J; Tanner M; Forsyth A; Cooke TG; Watters AD; Bartlett JM
    Clin Cancer Res; 2004 Jul; 10(14):4793-8. PubMed ID: 15269154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of dual immunohistochemistry and chromogenic in situ hybridization for HER2 on a single section.
    Reisenbichler ES; Horton D; Rasco M; Andea A; Hameed O
    Am J Clin Pathol; 2012 Jan; 137(1):102-10. PubMed ID: 22180483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of HER2 overexpression with gene amplification and its relation to chromosome 17 aneuploidy: a 5-year experience with invasive ductal and lobular carcinomas.
    Nassar A; Khoor A; Radhakrishnan R; Radhakrishnan A; Cohen C
    Int J Clin Exp Pathol; 2014; 7(9):6254-61. PubMed ID: 25337277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.